Retatrutide and joint pain is an emerging area of interest as this investigational triple receptor agonist progresses through clinical trials. Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, distinguishing it from currently approved therapies such as semaglutide and tirzepatide. Although Phase 2 data have demonstrated impressive cardiometabolic benefits, retatrutide remains unlicensed by the MHRA and EMA, meaning its full side-effect profile — including any musculoskeletal effects — is not yet formally established. This article reviews what is currently known, who may be at risk, and how joint symptoms should be managed and reported.

Can Retatrutide Cause Joint Pain?

No confirmed causal link between retatrutide and joint pain exists, as the drug remains unlicensed and its full side-effect profile is not yet established through post-marketing surveillance.

Retatrutide is an investigational triple receptor agonist currently under clinical development. It targets three incretin-related receptors simultaneously — the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action distinguishes it from existing approved therapies such as semaglutide or tirzepatide. Published Phase 2 data (Jastreboff et al., New England Journal of Medicine, 2023) demonstrated substantial reductions in body weight and improvements in cardiometabolic markers.

As of the time of writing, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). Phase 3 trials are ongoing; current development status can be verified via ClinicalTrials.gov or the sponsor's published trial registry entries. Because retatrutide remains unlicensed, its full side-effect profile has not been formally established through post-marketing surveillance. Consequently, there is no confirmed causal link between retatrutide and joint pain based on regulatory-approved prescribing information.

That said, musculoskeletal symptoms — including joint discomfort, arthralgia, and back pain — have been observed across the broader class of incretin-based therapies. Whether retatrutide specifically contributes to joint pain remains an area of ongoing investigation. Patients and clinicians should be aware that any new or worsening joint symptoms arising during participation in a clinical trial should be documented and reported to the trial team promptly. It is important not to dismiss such symptoms, even in the absence of a confirmed pharmacological mechanism.

What the Clinical Evidence Says About Musculoskeletal Side Effects

Phase 2 trial data for retatrutide primarily identified gastrointestinal side effects; arthralgia is recognised in approved incretin therapies but has not been prominently characterised for retatrutide pending Phase 3 results.

Published Phase 2 trial data for retatrutide (Jastreboff et al., NEJM, 2023) demonstrated significant reductions in body weight and improvements in cardiometabolic markers. The most commonly reported adverse effects in these trials were gastrointestinal in nature — including nausea, vomiting, diarrhoea, and constipation — consistent with the GLP-1 receptor agonist class effect. Musculoskeletal side effects were not prominently highlighted as primary adverse outcomes in the published Phase 2 data.

Arthralgia (joint pain) is listed as an adverse reaction in the UK Summaries of Product Characteristics (SmPCs) for approved incretin-based therapies. For semaglutide (Wegovy and Ozempic SmPCs, MHRA/EMC), arthralgia is listed as a common adverse reaction (occurring in ≥1/100 to <1/10 patients). For tirzepatide (Mounjaro SmPC, MHRA/EMC), arthralgia is similarly listed. Clinicians and patients should consult the current UK SmPC for each product for the most up-to-date frequency data.

A possible association between DPP-4 inhibitors — a related class of diabetes medicine — and severe joint pain was the subject of a US FDA safety communication in 2015. This signal has not been consistently replicated across incretin-based therapies as a whole, and no equivalent MHRA Drug Safety Update or EMA/PRAC communication has been issued specifically for GLP-1 receptor agonists in this regard. The US FDA data are noted here for context only and should not be directly extrapolated to retatrutide or other incretin classes without further evidence.

For retatrutide specifically, Phase 3 trial data are still being collected and analysed. Until these results are published and reviewed by regulatory bodies, the musculoskeletal side-effect profile cannot be definitively characterised. Clinicians involved in trial oversight should ensure that any musculoskeletal adverse events are captured systematically within trial protocols. Patients should be encouraged to report all symptoms to their trial coordinator or supervising clinician, as this contributes to the broader evidence base needed for regulatory assessment.

Who May Be at Greater Risk of Joint-Related Symptoms

Patients with pre-existing arthritis, obesity-related joint loading, or older age are at greater baseline risk; rapid weight loss may also transiently alter joint mechanics during treatment.

Whilst a direct causal link between retatrutide and joint pain has not been established, certain patient populations may be more predisposed to experiencing musculoskeletal symptoms during treatment — whether related to the medication itself or to the physiological changes it induces.

Individuals who may be at greater risk include:

• Those with a pre-existing diagnosis of osteoarthritis, rheumatoid arthritis, or other inflammatory joint conditions

• Patients with obesity-related joint loading, particularly affecting the knees, hips, and lower back

• Older adults, in whom musculoskeletal complaints are more prevalent at baseline

• Individuals experiencing rapid weight loss, which may transiently alter joint mechanics and gait, particularly in the lower limbs — this is a theoretical consideration based on general musculoskeletal principles rather than retatrutide-specific evidence

Significant weight reduction — one of retatrutide's primary therapeutic effects — is generally associated with reduced mechanical load on weight-bearing joints, which may improve joint symptoms over time in individuals with obesity-related arthropathy. NICE guidance on osteoarthritis (NG226: Osteoarthritis in over 16s: diagnosis and management) and obesity management (CG189: Obesity: identification, assessment and management) both acknowledge the musculoskeletal benefits of sustained weight loss, including improvements in knee and hip pain. The NHS also provides patient-facing information on the benefits of weight management for joint health.

Nevertheless, the transition period during active weight loss may be accompanied by transient musculoskeletal discomfort or altered physical activity patterns. Clinicians should take a thorough baseline musculoskeletal history before initiating any weight-management pharmacotherapy, including investigational agents such as retatrutide, to allow for meaningful comparison if symptoms arise during treatment.

Managing Joint Pain Whilst Taking Retatrutide

Management should follow NICE NG226 guidance, prioritising exercise, physiotherapy, and topical NSAIDs; trial participants must not stop retatrutide without consulting their trial team.

If joint pain develops during treatment with retatrutide — whether as part of a clinical trial or in any other context — a structured and pragmatic approach to management is advisable. The first step is to document the onset, location, severity, and character of the pain, noting whether it is associated with movement, rest, swelling, or systemic features such as fever or fatigue. This information is essential for distinguishing between mechanical joint pain, inflammatory arthritis, and other potential causes.

For mild to moderate joint discomfort without red flag features, management should be guided by NICE NG226 (Osteoarthritis in over 16s: diagnosis and management) and may include:

• Exercise and physiotherapy, which are central to NICE-recommended management; supervised exercise can strengthen periarticular muscles and reduce joint loading

• Topical NSAIDs (e.g., topical diclofenac) as a preferred first-line pharmacological option for localised joint pain, particularly in older adults where systemic NSAID use carries greater risk

• Paracetamol is not routinely recommended by NICE for osteoarthritis-type pain but may be considered for short-term use if other options are unsuitable or not tolerated

• Cold or warm compresses for symptomatic relief

If oral NSAIDs are considered necessary, they should be used at the lowest effective dose for the shortest possible duration, on medical advice, and with gastroprotection (a proton pump inhibitor) as recommended by NICE. Key contraindications and cautions include chronic kidney disease, heart failure, peptic ulcer disease, and elevated cardiovascular risk — all of which may be relevant in patients with obesity or metabolic syndrome. Clinicians should refer to the BNF and NICE CKS guidance on NSAIDs for full prescribing information.

It is important that participants in a clinical trial do not stop taking retatrutide without first consulting their trial team, as this may have implications for trial integrity and individual health outcomes. Any changes to the treatment regimen should be made collaboratively with the supervising clinician and documented appropriately.

When to Seek Medical Advice From Your GP or Specialist

A hot, swollen, or acutely painful joint — especially with fever — requires same-day assessment; all new symptoms must also be reported to the trial coordinator as potential adverse events.

Patients taking retatrutide — whether within a clinical trial setting or otherwise — should be aware of the circumstances that warrant prompt medical review. Whilst mild, transient joint discomfort may not require urgent attention, certain features should prompt timely consultation with a GP, trial physician, or relevant specialist.

Seek same-day medical assessment via your GP, NHS 111, an urgent treatment centre, or A&E if you experience:

• A hot, red, swollen joint — particularly if accompanied by fever or feeling generally unwell, as this may indicate septic arthritis (joint infection), which requires urgent treatment

• Sudden onset of severe joint pain, particularly if affecting a single joint (which may also suggest acute gout or another acute arthropathy)

Contact your GP or supervising clinician promptly if you experience:

• Joint swelling, redness, or warmth without systemic features, which may suggest an inflammatory process

• Joint pain accompanied by unexplained fatigue or other systemic symptoms

• Pain that significantly limits your mobility or daily activities

• Any new neurological symptoms alongside joint pain, such as numbness or weakness

In the context of a clinical trial, participants must also notify their trial coordinator of any new symptoms, as these may constitute adverse events requiring formal reporting under the trial protocol. Clinical trials involving investigational medicinal products (CTIMPs) in the UK are governed by the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended), with safety reporting requirements set out in MHRA and Health Research Authority (HRA) guidance. All adverse events — including musculoskeletal complaints — must be recorded and assessed for potential relatedness to the investigational product by the trial team.

For patients with pre-existing joint conditions, it is advisable to maintain regular contact with their rheumatologist or orthopaedic specialist throughout the course of treatment. Early intervention is generally associated with better outcomes, and clinicians should not attribute new joint symptoms solely to pre-existing conditions without appropriate reassessment.

Reporting Side Effects Through the MHRA Yellow Card Scheme

Trial participants must report adverse events including joint pain to their trial team; suspected side effects outside a trial can be reported to the MHRA via the Yellow Card scheme.

The MHRA's Yellow Card scheme is the UK's pharmacovigilance system for reporting suspected adverse drug reactions (ADRs). It plays a vital role in post-marketing surveillance for licensed medicines, and also accepts reports relating to unlicensed medicines, vaccines, medical devices, and e-cigarettes. Both healthcare professionals and members of the public can submit reports via the Yellow Card website (yellowcard.mhra.gov.uk) or through the Yellow Card app.

If you are taking retatrutide as part of a clinical trial, adverse events — including joint pain — should be reported directly to your trial team or sponsor in accordance with the trial protocol. This is the required route under the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) and MHRA/HRA guidance on CTIMP safety reporting. The trial team is responsible for assessing and formally reporting serious adverse events to the MHRA and ethics committee as required.

If you believe you have experienced a side effect in connection with retatrutide outside of a formal trial setting, you are encouraged to report this via the Yellow Card scheme. Reporting suspected side effects — even when causality is uncertain — contributes to the collective understanding of a medicine's safety profile.

When submitting a Yellow Card report, it is helpful to include:

• The name of the medicine and batch number (if known)

• A description of the suspected side effect, including onset, duration, and severity

• Any other medicines being taken concurrently

• Relevant medical history

The MHRA uses aggregated Yellow Card data to identify emerging safety signals, update product information, and, where necessary, take regulatory action. Encouraging a culture of reporting among both patients and clinicians is essential to ensuring that medicines, including novel agents such as retatrutide, are used as safely as possible.

Frequently Asked Questions